Member Info for Jonah58

Great stuff Isphahan. That’s a significant investment. Just hope it works out well for you. Your buy in price is certainly favourable.

Good point Seis. Taking this one stage further, perhaps they have lined up a potential source but transport would present problems during the rainy season. I couldn’t see why using the new front end was being delayed till after the rains.

The SA sale still awaits SA approval, Happy ,so we will be benefiting from the current surge in the basket price until that goes through.

I’d go for a dividend, BU. Bird in the hand and all that. But Leon has got his eyes on a refinery at Roan. That won’t be cheap.

Weaning

Good points Vik. The tapering/withdrawing steroids bit is interesting. I banged on about steroids on this forum at the time of the first phase 3 trials, arguing that reduced steroid requirement should have been a secondary end point. No one will remember the debate except, possibly, Nolupus.

A lot of candidates for the new trial will have been on steroids for a long time and wearing them off will not be easy and a headwind to recruitment. I’m not going to argue with the FDA, though and am looking forward to seeing the trial design.

‘Frontiers in Immunology’ is a peer reviewed journal.

Https://pmc.ncbi.nlm.nih.gov/articles/PMC9199391/

…artificial ceiling on the activated B cells count …

Without wishing to be condescending (which I am not) you could start by asking chat gpt about it.

It will reassure you that P140 does not impose an artificial ceiling on your B cells when presented count. There will still be a response to infection, albeit starting from a lower level, and the cells will be the right sort.

PS Very sympathetic about the psoriasis. It can be a miserable condition.

Bobby socks, you have oversimplified the issue. The problem in autoimmune disease is inappropriate activation of the immune system. There are two ways inappropriately activated cells can be reduced. There traditional way is to prevent them forming in the first place, immunosuppression. It is a blunt tool as you say. The other way is to promote their removal, not by attacking them but by activating a process of programmed cell death, known as apoptosis. Check it out, it is fundamental to the mode of action P140 and will not prevent the formation of appropriate new B cells when presented with an antigen challenge by, for example, an infection. Calm it down, but it still works.

That’s what happens in the laboratory, but the phase 3 trials must be done and are crucial. Investors may be counting their chickens. Patients with lupus wait in hope and expectation.

Spot on Cardo and 3card. But, enough of history. If you understand the financial future of a company, you don’t invest 30 grand of your hard earned cash in it on a whim. Good news today.

That’s right 3card. Sable was configured to switch easily between zinc and copper. Plan A was to process zinc from the dump plus additional material from Bird’s Star Zinc, leaving the lead and vanadium for later when further processing lines were installed.

I agree with Seis that we have no other zinc assets in Zambia so when zinc is mentioned in an interview it means Kabwe. If someone offered, Bottomsup could be right. Why does everything have to be so obscure. If we have disposed of Kabwe, that is material and highly relevant news.

Harmy, your AI bot is right and wrong. Right, we don’t own the Kabwe mine. Wrong, we do own the processing rights to the huge waste dump unless Bottomsup is correct in speculating this was the undisclosed non-core asset sold to an undisclosed buyer for $12 M.

The dump at Kabwe is a complex legacy issue. We acquired it very early in our foray into Zambia and, in fact, our original plan was to monetise this asset by extracting lead zinc and vanadium. Then the price of vanadium tanked and we got distracted by copper.

Responsibility for the pollution has been the subject of legal debate and threatened group action for decades. The WHO, World Bank and Zambian government are involved.

We have done some clean up work, i believe but agree that it is a festering sore that demands attention.

I couldn’t answer that without a lot more information. My guess is that we would not have to go back to phase 2 trials. We did the dosage and safety work recommended by the FDA.

Looks like it Steve. £145 per mg. Not for sale to individuals. Not formulated for medical use. Presumably being offered as a peptide to research institutions.

I think your post is overly cynical, Hope2. I have been involved with the industry in one way or another for a lifetime, and what you say a distortion of reality.

Big Pharma need to make big profits from their successful drugs to fund the huge expense of developing products that eventually fail (which is the norm).

A lot of cheerleaders about, but there’s no denying the exciting prospects raised by the RNS.

Now that the deal has gone through, I make no apology for asking a question that has been asked several times already, but I don’t recall seeing a credible answer. Since the $90 M is being paid in instalments, we retain interest in the SA business with a dwindling share over the next few years. It was made clear that this involves some continuing managerial input, but will we receive a proportional share of profits over that period (or be partially liable for any losses)?

Hi Bfish. Welcome to the board! Yes, Tjate is a deep mine and would cost hundreds of millions if not billions to develop. We would need a sustained rise in the basket price before anyone would be interested. I still believe the hydrogen economy will take off and although other cheaper catalysts are under investigation, platinum is still the favoured one for fuel cells. The most likely buyer under those circumstances would be one of our neighbours. In fact, the sale of a corner of our reef was once on the table, but it did not proceed. As Gotreal says, it might be worth something some time but in the current state it is worth nothing on my balance sheet!